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Abstract: In this study, we first measured some cytokine concentrations in the serum of 
patients treated with Juzentaihoto (JTT). Of the cytokines measured interleukin (IL) -18 was 
the most prominently up-regulated cytokine in the serum of patients under long term JTT 
administration. We next evaluated the effects of JTT in mice, focusing especially on natural 
killer T (NKT) cell induction. Mice fed JTT were compared to control group ones. After 
sacrifice, the liver was fixed, embedded and stained. Transmission electron microscope 
(TEM) observations were performed. Although the mice receiving the herbal medicine had 
same appearance, their livers were infiltrated with massive mononuclear cells, some of 
which were aggregated to form clusters. Immunohistochemical staining revealed that there 
was abundant cytokine expression of IL-12 and IL-18 in the liver of JTT treated mice. To 
clarify what the key molecules that induce immunological restoration with JTT might be, we 
next examined in vitro lymphocyte cultures. Mononuclear cells isolated and prepared from 
healthy volunteers were cultured with and without JTT. Within 24 hours, JTT induced the 
IL-12 and IL-18 production and later (72 hours) induction of interferon (IFN)-gamma. Oral 
administration of JTT may induce the expression of IL-12 in the early stage, and IL-18 in the 
chronic stage, followed by NKT induction. Their activation, following immunological 
restoration could contribute to anti-tumor effects. 
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1. Introduction 
 
Before the modern use of synthetic drugs, many medicines worldwide were derived from natural 
plant sources, including the nuts, roots and leaves. In Asian countries, especially in ancient China, 
many botanical materials had been adapted into medicines and these compositions have been described 
in old medicical encyclopedias.   
Kampo originally means “Chinese style”, not only in medicine, but also for other Japanese words 
describing life styles. Kampo these days has come to mean “ethnical traditional medicine”. The 
principles of Kampo drugs were originally based on old Chinese traditional medicines and comprise 
about one hundred and fifty kinds of compositions of natural herbs and other natural products. Kampo 
medicine is generally characterized by its low frequency of severe adverse effects and is used in 
current clinical practice all over Japan and other countries.   
Kampo products, for example, herbal extract granules for ethical use, were first included under the 
coverage of the Japanese public health insurance system in 1976 and currently, many clinical doctors 
in Japan apply these Kampo medicines along with Western chemically synthesized drugs [1].   
Kampo traditional medicine is based on the long experience with its use in China and other oriental 
countries. The main theory of this medicine is based on the concept that diseases are caused from a 
disharmony of bodily flow and the aim of therapy is treating the patient as a body, not the disease. 
Consequently there can many ways to treat individual patients with the same disease.   
“Sho”, the term of traditional Kampo medicine, refers to a particular pathological status of a patient 
evaluated by Kampo diagnosis, and is patterned according to the patient’s constitution and symptoms, 
among other considerations [1]. Kampo preparations, including Japanese traditional botanical 
medicines, should be used after confirmation that it is suitable for the identified Sho of the patient. 
Based on the particular diagnosis for Sho, some herbs and other natural materials should be 
compound into drugs. Originally they were taken as soluble extract in hot water just like tea, but now it 
can easily be taken as granular essence style drugs controlled under the Japanese Pharmacopoeia. Over 
ten pharmaceutical companies in Japan produce these granular style Kampo drugs for increased patient 
convenience [1].   
Recently the use of alternative and complementary medicines in the Western countries has become 
more popular and some Kampo medicines can now be used in these countries. The use of Kampo style 
medicines is evolving how comprehensive medicine is practiced with established Western medical 
drugs. 
Juzentaihoto (JTT), one of the Kampo Japanese herbal medicines was first described as 
Si-Quan-Da-Bu-Tang in Daipinghuimin-Hejijufang (the Drug text book in Song Dynasty, 1151 A.D. in 
ancient China) and introduced into Japan in the Kamakura dynasty, about eight hundred years ago. The 
name of this drug originates from its Han–letters. This is composed with four parts of characters in the 
name, “Juzen” means perfect, “tai” means great, “ho” means supplement, and “to” means water drug, 
respectively, and it consists from ten crude components obtained from natural herbs (shown in Table 1 
from the 2006 Japanese Pharmacopoeia) [2].   Int. J. Mol. Sci. 2008, 9    1144
 
 
 
Table 1. Botanical origins of ten crude drugs of JTT from the 2006 Japanese 
Pharmacopoeia. 
Crude Drugs  Scientific Name of Botanical Origin  Ratio 
Astragali Radix  Astragalus membranaceus Bunge or A. mongholicus Bunge 3.0 
Cinnamomi Cortex  Chinnamomum cassia Mlume or other species of the same 
genus 
3.0 
 
Rehmanniae Radix  Rehamannia glutinosa Liboschitz var. 
Purpurea Makino or A. glutinosa Liboschitz 
3.0 
 
Paeoniae Radix  Paeonia lactiflora Pallas or allied plants  3.0 
Cnidii Rhizoma  Cnidium officinale Makino  3.0 
Atractylodis 
Lanceae Rhizoma 
Atractylodes launcea De Candolle or A. chinesis Koidzumi  3.0 
Angelicae Radix  Angelica acutiloba Kitagawa or allied plants  3.0 
Ginseng Radix  Panax ginseng C.A. Meyer  3.0 
Hoelen  The sclerotium of Poria cocos Wolf 3.0 
Glycyrrhizae Radix  Glycyrrhiza  uralensis Fischier, G. grabra Linne, or other 
species of the same genus 
 
 
It has been mainly administrated to patients depressed or weakened by long illness to improve their 
general condition. The intended effect of this drug is to treat weakened conditions after illness, pale 
complexion, general fatigue, loss of appetite, night sweats, cold extremities, dry skin, dry mouth and 
anemia. Recently there have been some reports that JTT has anti-tumor effects and may prolong the 
survival of cancer patients [3-6]. Other reports describe that decreased occurrence of secondary 
carcinogenesis [7-11].   
These pharmacological mechanisms by which JTT exerts its effects have not yet been clarified. One 
study reports JTT cause the induction of interleukin (IL)-12 and subsequent activation of natural killer 
T (NKT) lymphoid cells [12-13]. Other work mentions IL-18 induction as a possible result of JTT. 
NKT cells are a type of lymphocyte characterized by their morphology which displays large 
granules in the plasma and has T cell receptors (TCR) with NK receptors, such as NK1.1. These cells 
have a role in both innate and adaptive immune responses [14]. Cytokines, such as IL-12 and IL-18, 
are important activators of NKT cells [15-18].   
In this paper we describe experiments in designed to determine the ability of JTT to induce IL-12 
and IL-18 and subsequent activation of NKT cells. 
2. Materials and Methods 
2.1. JTT 
The herbal medicine, Juzentaihoto (JTT) was obtained from Tsumura Co. Ltd. (Tokyo, Japan) for 
this study. The quality of ten crude drugs shown in Table 1 is described by the 2006 Japanese 
Pharmacopeia. The patients who were treated in our hospital were taking JTT at a dosage of 7.5 g/day, 
125 mg /kg/day or 4600 mg/m
2 of. Mice were treated with 0.2% or 1.0% (w/w) drug mixed with chow. 
Assuming the mice weighed 25 g and ate 5 g per day, their exposures ranged from 1,200 mg/m
2 to Int. J. Mol. Sci. 2008, 9    1145
 
 
 
6,000 mg/m
2. The estimated dose levels in mice were calculated to bracket the estimated human 
exposure. 
2.2. Patients 
Patients have been treated in our hospital for many kinds of diseases, especially for liver function 
disorders. Twelve patients of liver cirrhosis with hepatocellular carcinoma were treated with/without 
JTT and compared to the same numbers of healthy volunteer and other disease (autoimmune diseases 
like Sjogren’s syndrome) patients. All patients made informed-consent for our study following the 
Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. 
2.3. ELISA 
To estimate the serum concentration of some cytokines, we used enzyme linked immunosorbent 
assay (ELISA) and followed the methods provided by the manufacturer. The source and sensitivity 
(lower limit of detection) of the ELISA kits are showed in Table 2. 
Table 2. Commercial ELISA kits used in this study (h: human, m: mice). 
Cytokine Kit  code  Production  Sensitivity 
hIL-1  RPN5971  GE Imagination at Work  >4 pg/mL 
hIL-2  JIMRO IL-2  Otsuka Pharma. Tokyo, Japan  >50 pg/mL 
hIL-4  S-4050  R & D Systems Inc. MN, U.S.A.  >15 pg/mL 
hIL-6  D-6050  R & D Systems Inc. MN, U.S.A.  >8 pg/mL 
hIL-12 (supernatant)  EHIL12  Pierce Biotech. Inc. IL, U.S.A  >3 pg/mL 
hIL-12 (serum)  P1200  R & D Systems Inc. MN, U.S.A.  >8 pg/mL 
hIL-18  #7260  Med. Biologic. Lab. Nagoya, Japan  >12.5 pg/mL 
hTNF-α  QTA00B  R & D Systems Inc. MN, U.S.A.  >0.5 pg/mL 
hIFN-γ  IM1743  Immunotech. Co. Marseille, France  >0.4 IU/mL 
mIL-12  M1270  R & D Systems Inc. MN, U.S.A.  >2.5 pg/mL 
mIL-18  #7625  Med. Biologic. Lab. Nagoya, Japan  >25 pg/mL 
2.4. Cell culture 
Mononuclear cells were prepared from healthy volunteers of this hospital by lymph-prep® 
(Immuno-Biological Lab., Takasaki, Japan) by recommended methods and dissolved in Dulbecco 
minimum essential medium (DMEM) with 5% fetal bovine serum (FBS) and some antibiotics. They 
were cultured with /without JTT and lymphocyte stimulation factor, like PMA (final concentration at 
10ng/mL) for 24, 48, and 72 hours. 
2.5. Mice 
A total of 60 six-week old female specific pathogen free (SPF) C57BL/6 mice were purchased from 
Japan CLEA (Saitama, Japan) and housed and maintained at 24 °C and constant 60% humidity in the 
Animal Laboratory of Showa University. They were randomly divided into some groups, five mice per 
group, and examined after one-week standardizing diet prior to dosing. Mice were observed for Int. J. Mol. Sci. 2008, 9    1146
 
 
 
changes in their body weight and appearance throughout study. Every group of mice were given 
arranged volume of drugs on the schedule and sacrificed according to the experimental animal 
protection regulations of Showa University.   
2.6. Pathological inspection 
Mice were killed one, three, six and twelve months after administration. The body and liver weight 
were recorded at each examination. Formalin fixed and paraffin embedded liver tissue sections were 
observed by hematoxylin eosin (HE) staining by optical microscope. Three pathologists have 
independently done this observation and assessment of the drug effects and the representative data 
were shown in the figures. 
2.7. TEM 
Transmission electron microscopic observation (TEM) has been done on the glutaraldehyde fixed 
and hydrophil-resin embedded specimens by common methods. 
2.8. Immunohistochemical staining (IHC) 
After 4% (w/w) paraformaldehyde/PBS fixation, specimens were immersed in 5, 15, 30% 
sucrose/PBS and frozen in OCT compound. Cryosections were carried out and stained with primary 
antibody shown in Table 3. After washing, sections were incubated with the secondary antibodies at the 
titer of 50%, biotinylated anti rat IgG made in goat (Vector Laboratories, Inc., USA, CA) and then 
colored with ABC kit (Vector Laboratories, Inc., USA, CA) and DAB solution. Counter staining was 
produced with methylgreen. 
Table 3. Primary antibodies used in this study 
Antigen Clone  Production 
TCRαβ  MO073207  Becton Dickinson Co. (NJ, U.S.A.) 
NKG2D  191004  TECHNE (Staffordshire, U.K.) 
IL-12  C15.6  Biosource International Inc. (CA. U.S.A.) 
IL-18  SC9464  Santa Cruz Biotech. Inc. (CA. U.S.A.) 
2.9. In situ hybridization mRNA analysis (ISH) 
ISH was performed by use of a manual capillary actions system (MicroProbeTM® Staining System, 
Fisher Scientific, GA, U.S.A.). The sequence of the anti-sense oligo-nucleotide probe used for ISH 
were with the motifs as TCRVα14; (5' AGG CTG AAC CTC TAT CCC CCA CCA CAC AGA 
3')products of Gene Reserch Lab® (Sendai, Japan).   
2.10. Statistical study 
Statistical tests were done with Student’s t-test for multiple comparisons adjusted for in the 
analysis. Int. J. Mol. Sci. 2008, 9    1147
 
 
 
3. Results 
3.1. Serum cytokines 
Serum from patients treated with JTT medicine showed no changes in the concentration of several 
serum cytokines (IL-1, IL-2, IL-4, IL-6, IL-12, TNF-α, IFN-γ, data not shown). These cytokines were 
undetectable by the ELISA in this study. These results of serum IL-18 are shown in Figure 1. IL-18 
levels were increased in patients treated with JTT for over one year, compared with sera from 
non-treated patients and healthy volunteers. There is no relation between IL-18 and CRP which one of 
the clinical indicators of inflammatory diseases (data not shown). For comparison purposes, the serum 
levels of IL-18 from patients with autoimmune diseases (not treated with JTT) are included in Figure 1. 
Figure 1. Serum concentrations of IL-18 from liver cancer (Ca), autoimmune disease 
(RA) patients and healthy volunteers (VO). JTT administration （JTT+) may result in 
induction of IL-18.   
 
A representative time course (0-24 weeks) of the changes in serum IL-18 concentration from JTT 
treated patients is shown in Figure 2. IL-12 concentration was also monitored along with IL-18, but there 
was no remarkable changes in IL-12 levels. 
3.2. Cell culture   
The peripheral mono nuclear cells prepared from healthy volunteers were cultured with JTT. It 
resulted in the high concentration of IL-12 and IL-18 production in the supernatant. Induction of 
cytokines occurred within 24 hours in this culture, and continued at least to 72 hours. IFN-γ production 
increased following after IL-12 and IL-18 induction. These results are shown in Figure 3. 
3.3. Pathological changes in liver 
Although there are no specific changes in appearance, body weight and liver weight of JTT treated 
mice (data not shown), these livers were infiltrated by massive mononuclear cells, some of which were 
aggregated to form clusters (Figure 4). Int. J. Mol. Sci. 2008, 9    1148
 
 
 
Figure 2. Serum Cytokine from the JTT Administrated Patient, IL-18 increased, other 
cytokines (IL-1, IL-2, IL-4, IL-6, IL-12, TNF-a, IFN-g, Data not shown) were not 
detectable in patient’s serum. 
 
Figure 3. Cytokine from Cultured PBMC with/without JTT. PBMC cultured with/without 
JTT in DMEM with 5% Bovine Calf Serum. JTT induced IL-12 and IL-18 production 
following IFN-g within 72 hours in vitro. 
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Figure 4. Mononuclear cell infiltration with JTT treatment.  Liver was infiltrated by 
massive mononuclear cells in JTT treated mice and some of which were aggregated to 
clusters (arrow head).   
 
 
 
 
 
 
 
 
Figure 5. Aggregated lymphocyte with JTT. There are some large granular lymphocytes, 
some of which have electron high dense granules in the cytoplasma, in the liver of JTT 
treated mice (TEM scan methods). 
 
3.4. TEM findings 
 
TEM observation indicated that there are some large granular lymphocytes, some of which have 
electron high dense granules in their cytoplasm, in the liver of JTT treated mice (Figure 5). The 
findings of these mononuclear cells are consistent with them being NKT cells. 
5 μmInt. J. Mol. Sci. 2008, 9    1150
 
 
 
3.5. NKT infiltration in the JTT treated mice Liver 
 
The IHC results showed that many of the infiltrating mononuclear cells abundantly expressed 
NKG2D, a reported selective NK marker and T cell receptor (TCR) on their surface (shown in Figure 
6). 
Figure 6. TCR Va14 expression on the surface of infiltrated mononuclear cells, detected by 
ISH (A) and NKG2D (B), TCR (C) by IHC method. 
 
 
 
 
 
 
 
 
 
3.6. ISH for Va14 
 
mRNA in situ hybridization method for Vα14, the specific T cell receptor of NKT, indicated that 
there were many Vα14 positive NKT cells infiltrating into the liver of JTT treated mice and forming 
the cluster. 
 
3.7. IL-12 expression on the JTT treated mice liver 
 
IHC analysis for the cytokine IL-12 revealed abundant expression of IL-12 on the cells infiltrated 
into liver of JTT treated mice. The expressions of IL -12 increased with longer drug exposure time 
(Figures 7-10) 
Figure 7. Expression of cytokines. The liver tissue from the control mice. They have   
expressed little of cytokines. 
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Figure 8. Expression of cytokines. The lice tissue from the 1% JTT short term treated mice. 
There are no expression of cytokines on some cells (arrow head). 
 
 
 
 
 
 
 
 
Figure 9. Expression of cytokines of the liver tissue from the 0.2% JTT long term treated 
mice. There are expression of cytokines on some cells which aggregated into clusters 
(arrow head). 
 
  
 
 
 
 
 
 
Figure 10. Expression of cytokines of the liver tissue from the 1% JTT long term treated 
mice. There are abundant expression of cytokines on some cells which aggregated into 
clusters (arrow head). 
  
 
 
 
 
 
 
 
3.8. IL-18 expression on the JTT treated mice liver 
 
IHC analysis for IL-18 expression revealed abundant cytokine levels was present on the cells from 
JTT treated mice liver. IL-18 expression had the same appearance with IL-12 (Figures 7-10). Long 
term JTT treatment induced up-regulation of serum cytokine concentration of IL-12, and IL-18. These 
results indicate that significant increase related with JTT concentration. (Figure 11) 
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Figure 11. Serum Cytokine from Long Term JTT treated Mice. JTT long term treatment 
included up-regulation of serum cytokine concentration of IL-12, and IL-18. These results 
indicate that significant increase related with JTT concentration. 
 
 
4. Discussion 
 
Herbal prescriptions like Japanese Kampo medicine have been recognized for their potential and 
clinical usefulness. Recently, Juzentaihoto (JTT), one of these Japanese botanical medicines, has been 
reported to experimentally display anti-tumor effects against liver metastasis. Through this study we 
attempted to reveal a possible pharmacological mechanism of JTT’s anti-tumor effects.   
First we compared the serum cytokines from treated and non-treated patients. JTT treated patients 
in our study appeared to have high serum concentrations of IL-18, compared with non-treated patients, 
but the levels of IL -18 showed no relation to their disease status, as indicated by serum CRP. IL-18 
was also up-regulated in serum from non JTT treated patients with liver cirrhosis, but to a lesser extent 
than in subjects treated with JTT. Although these patients do not formally have hepatocellular 
carcinoma, they represent a patient population at risk for developing liver cancer and may be viewed 
as pre-cancerous, which might be the reason for the elevated IL-18 levels in the untreated cirrhotic 
patients. IL-18 from the serum of autoimmune disease patients were also slightly up-regulated 
compared with healthy volunteers. This might be from activated immuno-reaction, but there is still 
question why the other cytokines were not changed. The evaluation of cytokines was performed with 
commercial ELISA kits according to manufacturer’s methods. These kits have satisfactory potential of 
detection of cytokine in these sensitivity (most have pg/mL sensitivity) and specificity. We were unable 
to detect measureable levels of several cytokines in this study, but since many cytokines are transiently 
expressed in vivo, and decline rapidly following induction, the fact that we could not detect several of 
the cytokines tested is not surprising.   
As the evaluation results of serum cytokines were not detected sufficiently in patient sera, we next 
constructed two experimental models. One is the cell culture method for in vitro cytokine production; 
the other is an animal model to look for tissue expression of cytokines in vivo. 
Human lymphocyte cultures incubated with JTT produced elevated levels of both IL-12 and IL-18. Int. J. Mol. Sci. 2008, 9    1153
 
 
 
One possible additional source of increased cytokines (i.e., IL -18) in the peripheral blood could be 
from mononuclear cells in tissues. INF-γ production was also up-regulated following after IL-12 and 
IL-18. Up-regulation of this pathway could be involved in the anti-tumor effects of JTT administration 
via TH1 lymphoid effects. 
Treatment of mice with JTT produced no significant changes for growth and liver function, yet in 
this study there were some interesting pathological results in the livers of JTT treated mice. Massive 
mononuclear cell infiltration and some of these were aggregated in clusters. These aggregated 
mononuclear cells are mainly considered NKT cells for their specific surface markers and for their 
characteristic intracellular structures. 
This report also shows that JTT administration might induce IL-12, which has been originally 
described as a NKT cell stimulatory factor, as well as IL-18 expression. Our results revealed many 
mononuclear cells, including dendritic cells and Kupffer cells in liver tissue of JTT treated mice and 
expressed abundant IL-12 and 1L-18.   
These cytokine expressions induced by JTT might be the reason of massive mononuclear cells, 
especially NKT cells infiltration and their activation, following immunological restoration could 
contribute to anti-tumor effects.   
 
Conclusions 
 
Although there is some vagueness concerning the ingredients and pharmacological efficiency of the 
ten crude components of the Japanese botanical medicine Juzentaihoto, the consumption of natural 
herbs has certain inductive effect on NKT cells. Further studies for elucidate the efficacy of natural 
herbs for disease treatment are recommended. Cancer patients are always at risk of developing a 
secondary malignancy, and JTT may help to decrease this risk without severe adverse effects. JTT, one 
of Japanese herbal medicine administration might be the alternative strategy of treatment for cancer 
patients to prevent secondary oncogenesis.   
 
Acknowledgements 
 
We are very thankful to Dr. Dennis M. Miller (ZymoGenetics, Seattle U.S.A.) for his useful 
recommendations and great support our study. We performed this work with support by the Grant-in 
Aid from Tokyo Metropolitan Government Clinical Research Foundation and the Grant-in-Aid for 
Scientific Research (16659051, 17076001, 18592008) and High-Tech Research Center Project for 
Private Universities from Ministry of Education, Culture, Sports, Science and Technology, Japan. 
 
References 
 
1.  Akiba, T.; Aoyama, R.; Arai, M.; Asaoka, T.; Cyong, J.C.; Fukuta, Y.; Fukuzawa, M.; Goto, T.; 
Hanawa, T.; Hara, K.; Introduction to KAMPO, Japanese Traditional Medicine. Sato, Y., Hanawa, 
T., Arai, M., Cyong, J.C., Fukuzawa, M., Mitani, K., Ogihara, Y., Sakiyama, T., Shimada, Y., 
Toriizuka, K., Yamada, T. (Eds.); Elsevier: Tokyo, Japan, 2005. 
2.  Japanese Pharmacopoeia XV edition; Ministery of Health, Labour and Welfare, Aimi, N.; Aoki, Int. J. Mol. Sci. 2008, 9    1154
 
 
 
M.; Aonuki, K.; Aoyagi, N.; Arakawa, Y.; Arimoto, K.; Ashizawa, K.; Aso, S.; Aso, Y.; Emura, M. 
et al. (Eds.); 2006; pp. 1734-1735. 
3.  Saiki, I.; Yamaura,T.; Ohnishi, Y.; Hayakawa, Y.; Komatsu, Y.; Nunome, S. HPLC analysis of 
Juzen-taiho-to and its variant formulations and their antimetastatic efficacies. Chem. Pharm. Bull. 
1999, 47, 1170-1174.   
4.  Hamada, M.; Fujii, Y.; Yamamoto, H.; Miyazawa, Y.; Shui, S. H.; Tung, C. Y.; Yamaguchi, N. 
Effect of kampo medicine, zyuzentaihoto, on the immuno reactivity of tumor-bearing mice. J. 
Ethnopharmacol. 1988, 24, 311-320.   
5.  Kiyohara, H.; Takemoto, N.; Komatsu, Y.; Kawamura, H.; Hosoya, E.; Yamada, H. 
Characterization of mitogenic oeptic polysaccharides from kampo (Japanese herbal) medicine 
“Juzen-Taiho-To”. Planta Med. 1991, 57, 254-259.   
6.  Utsuyama, M.; Seidlar, H.; Kitagawa, M.; Hirokawa, K. Immunological restoration and 
anti-tumor effect by Japanese herbal medicine in aged mice. Mechan. Age. Develop. 2001, 122, 
341-352. 
7.  Saiki, I. A Kampo medicine “Juzen-taiho-to” prevention of malignant progression and metastasis 
of tumor cells and the mechanisms of action. Biol. Pharm. Bull. 2000, 23, 677-688. 
8.  Maruyama, H.; Kawamura, H.; Takemoto, N.; Komatsu, Y.; Aburada, M.; Hosoya, E. Effect of 
Juzentaihoto on phagocytes. Jpn. J. Inflamation 1988, 8, 461-465.   
9.  Haranaka, K.; Satomi, N.; Sakurai, A.; Haranaka, R.; Okada, N.; Kobayashi, M.; Antitumor 
activities and tumor necrosis factor producibility of traditional Chinese medicine and crude drugs. 
Cancer Immunol. Immunother. 1985, 20, 1-5. 
10.  Kubota, A.; Okamura, S.;. Shimoda, K. A traditional Chinese herbal medicine, Juzen-taiho-to, 
augments the production of granulocyte/macrophage colony-stimulating factor from human 
peripheral blood mononuclear cells in vitro. Int. J. Immunother. 1992, 8, 191-195. 
11.  Ohnishi, Y.; Fujii, H.; Hayakawa, Y.; Sakukawa, R.; Yamaura, T.; Sakamoto, T.; Tsukada, K.; 
Fujimaki, M.; Nunome, S.; Komatsu, Y.; Saiki, I. Oral administration of a Kampo(Japanese 
herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn. J. 
Cancer Res. 1998, 89, 206-213. 
12.  Cui, J.; Shin, T.; Kawano, T.; Sato, H.; Kondo, E.; Toura, I.; Kaneko, Y.; Koseki, H.; Kanno, M.; 
Taniguchi, M.; Requirement for Vα14 T cells in IL-12-mediated rejection of tumors. Science 
1997, 278, 1623-1626. 
13.  Matsumoto, T.; Sakurai, H. M.; Kiyohara, H.; Yamada, H. Orally administered decoction of 
Kampo (Japanese herbal) medicine “Juzen -Taiho –To” modulates cytokine secretion and induces 
NKT cells in mouse liver. Immunopharmacology 2000, 46, 149-161. 
14.  Adachi, Y.; Koseki, H.; Zulstra, M.; Taniguchi, M. Positive selection of invariant Vα14+ T cells 
by non-major histocompatiblility complex-encoded class I-like molecules expressed on bone 
marrow-derived cells. Proc. Natl. Acad. Sci. 1995, 92, 1200-1204. 
15.  Tsutsui, H.; Matsui, K.; Okamura, H.; Nakanishi, K. Pathophysiological role of interleukin-18 in 
inflammatory liver disease. Immunol Rev. 2000, 174, 192-209. 
16.  Kobayashi, M.;. Fitz, L.; Ryan, M.; Hewick, M.R.; Clark, C.S.; Chan, S.; Loudon, R.; Sherman, 
F.; Perussia, B.; Trinchieri, G. Identification and purification of natural killer cell stimulatory 
factor, a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 1989, 170, Int. J. Mol. Sci. 2008, 9    1155
 
 
 
827-845. 
17.  Hsieh, S. C.; Macatonia, E. S.; Tripp, S. C.; Wolf, F. S.; O’Garra, A.; Murphy, M. K. Development 
of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 
260, 547-549. 
18.  Matsuda, T.; Uzuki, M.; Uchida, T.; Nakamura, M.; Tai, M.; Shiraishi, N.; Sazaki, N.; Yakushiji, 
F.; Tomiyama, J.; Suzuki, S.; et al. Induction of Mononuclear Cell Infiltration into Liver by the 
Japanese Herbal Medicine, Drugs Exp. Clin. Res. 2005, 31, 207-214. 
 
© 2008 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This 
article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/3.0/). 